Short answer
Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on September 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). $4.7B senior notes issued across euro and dollar markets, extending Teva’s debt maturities through 2037.
Teva Pharmaceutical Industries Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $4.7B senior notes issued across euro and dollar markets, extending Teva’s debt maturities through 2037
- Coupon rates range from 4.250% to 5.750%, creating substantial ongoing interest expense
- Proceeds primarily fund redemption of higher-coupon notes, including 8.125% notes due 2031 and 7.875% notes due 2029
- Refinancing may reduce borrowing costs, while maintaining significant leverage and senior unsecured obligations guaranteed by Teva
- Conditional redemptions include up to €1.15B of 4.375% notes due 2030 and $450M of 4.750% notes due 2027
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Teva Pharmaceutical Industries Ltd 8-K filings
Get the next TEVA 8-K as it lands
Follow TEVA for push alerts, or ask the research agent what this filing means.